Skip to main content
Fig. 2 | Trials

Fig. 2

From: Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial

Fig. 2

The schedule of enrolment, interventions, and assessments. ACR, American College of Rheumatology; CDAI, clinical disease activity index; DAS28, Disease Activity Score-28; EQ-5D-5L, EuroQol-5 Dimension 5-Level; ESR, erythrocyte sedimentation rate; FACIT-F, Functional Assessment of Chronic Illness-Fatigue; HAQ-DI, Health Assessment Questionnaire Disability Index; MSUS, musculoskeletal ultrasound; SDAI, simplified disease activity index

Back to article page

Trials

ISSN: 1745-6215